No CrossRef data available.
Published online by Cambridge University Press: 07 March 2012
A novel nanoparticulated form of the poorly water-soluble anticancer drug paclitaxel (PTX) suitable for intravenous administration has been developed using sonication-assisted layer-by-layer (LbL) assembly. The nanoparticles contain up to 70 wt.% of the drug and consist of 150-180 nm solid crystal paclitaxel cores coated with 20-30 nm thick shells of alternative layers of PEGylated poly-L-lysine and heparin. Dispersions of PTX nanoparticles are stable in different biological solvents at concentrations up to 5 mg/ml. Intravenous administration of the LbL-coated nano-crystalline PTX to mice via tail injection provided the preliminary confirmation of their safety and tolerability.
Full text views reflects PDF downloads, PDFs sent to Google Drive, Dropbox and Kindle and HTML full text views.
* Views captured on Cambridge Core between September 2016 - 14th April 2021. This data will be updated every 24 hours.